Patents by Inventor Ernest Loumaye

Ernest Loumaye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12280052
    Abstract: The present disclosure provides compositions and methods for treating endometrial growth disorders in a patient, such as a human patient, and particularly pre-menopausal female human patients. Exemplary disorders that may be treated using the compounds and therapeutic regimens described herein include adenomyosis and rectovaginal endometriosis. The compounds described herein that may be used to treat such indications include gonadotropin-releasing hormone (GnRH) antagonists. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof, among others.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: April 22, 2025
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Jean-Pierre Gotteland, Ernest Loumaye
  • Patent number: 11980621
    Abstract: The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Müllerian hormone (AMH) or ?17-estradiol (E2).
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 14, 2024
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Ernest Loumaye, Jean-Pierre Gotteland
  • Patent number: 11759464
    Abstract: The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny I]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: September 19, 2023
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Ernest Loumaye, Jean-Pierre Gotteland, Oliver Pohl
  • Patent number: 11524003
    Abstract: The invention provides ?-amino esters of a hydroxypropylthiazolidine carboxamide derivative, (2S)-3-([1,1?-biphenyl]-4-ylsulfonyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]-1,3-thiazolidine-2-carboxamide, as well as salts and crystal polymorphs thereof, that can be used to inhibit prostaglandin F receptor. The invention further encompasses methods of treating disorders such as preterm labor at the early gestational stage by the administration of these substances to a patient in need of treatment.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: December 13, 2022
    Assignee: ObsEva S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Ernest Loumaye, Oliver Pohl, Jean-Pierre Gotteland
  • Patent number: 10555934
    Abstract: The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 11, 2020
    Assignee: ObsEva S.A.
    Inventors: Patrick Naxos Page, Matthias Schwarz, Catherine Jorand-Lebrun, Anna Quattropani, Vincent Pomel, Ernest Loumaye, Oliver Pohl, Jean-Pierre Gotteland
  • Patent number: 10441593
    Abstract: The present invention relates generally to gynecological diseases and in particular to a method for reducing pain associated with dislocation of basal endometrium.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: October 15, 2019
    Assignee: PREGLEM S.A.
    Inventors: Ernest Loumaye, Elke Bestel, Ian Osterloh
  • Patent number: 10441534
    Abstract: The present invention relates generally to a combination for use in the treatment of gynaecological diseases and associated disabling symptoms thereof, in a subject in need thereof, said pharmaceutical combination for use comprising co-administering a suitable pharmaceutical composition for oral administration comprising a first progesterone receptor modulator and a pharmaceutical composition suitable for vaginal and/or intrauterine administration comprising a second progesterone receptor modulator.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: October 15, 2019
    Assignee: PregLem SA
    Inventors: Jean-Pierre Gotteland, Valérie Boujac, Ernest Loumaye
  • Publication number: 20190262361
    Abstract: The present invention relates to a long-term therapy including repeated treatment courses of ulipristal acetate or any metabolite thereof for treating uterine fibroids. The present invention also relates to a combined therapy applying ulipristal acetate with a progestin in order to improve the currently used treatment for uterine fibroids.
    Type: Application
    Filed: December 21, 2018
    Publication date: August 29, 2019
    Applicant: PregLem SA
    Inventors: Elke Bestel, Ian Osterloh, Ernest Loumaye, Annie Dacquin, Florence Jean
  • Patent number: 9168264
    Abstract: The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 27, 2015
    Assignee: PREGLEM SA
    Inventors: Ernest Loumaye, Elke Bestel, Ian Osterloh
  • Publication number: 20150065470
    Abstract: The present invention is related to a dosage regimen of a steroid sulfatase inhibitor, E2MATE, for use in the prevention or treatment of endometriosis. The present invention further relates to a method for preventing or treating endometriosis.
    Type: Application
    Filed: April 4, 2013
    Publication date: March 5, 2015
    Applicant: PregLem SA
    Inventors: Ernest Loumaye, Oliver Pohl, Jean-Pierre Gotteland
  • Publication number: 20150051180
    Abstract: Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.
    Type: Application
    Filed: October 7, 2013
    Publication date: February 19, 2015
    Applicant: PregLem S.A.
    Inventors: Bartholomeus C.J.M. Fauser, Ernest Loumaye
  • Publication number: 20150038476
    Abstract: The present invention relates generally to a combination for use in the treatment of gynaecological diseases and associated disabling symptoms thereof, in a subject in need thereof, said pharmaceutical combination for use comprising co-administering a suitable pharmaceutical composition for oral administration comprising a first progesterone receptor modulator and a pharmaceutical composition suitable for vaginal and/or intrauterine administration comprising a second progesterone receptor modulator.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 5, 2015
    Applicant: PregLem SA
    Inventors: Jean-Pierre Gotteland, Valérie Boujac, Ernest Loumaye
  • Publication number: 20140148419
    Abstract: The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.
    Type: Application
    Filed: July 12, 2012
    Publication date: May 29, 2014
    Applicant: PREGLEM SA
    Inventors: Ernest Loumaye, Elke Bestel, Ian Osterloh
  • Publication number: 20140100208
    Abstract: Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.
    Type: Application
    Filed: October 7, 2013
    Publication date: April 10, 2014
    Applicant: PregLem S.A.
    Inventors: Bartholomeus C.J.M. Fauser, Ernest Loumaye
  • Patent number: 8569274
    Abstract: Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: October 29, 2013
    Assignee: Preglem S.A.
    Inventors: Bartholomeus C. J. M. Fauser, Ernest Loumaye
  • Publication number: 20130281422
    Abstract: The present invention relates generally to gynecological diseases and in particular to a method for reducing pain associated with dislocation of basal endometrium.
    Type: Application
    Filed: December 23, 2011
    Publication date: October 24, 2013
    Applicant: PREGLEM S.A.
    Inventors: Ernest Loumaye, Elke Bestel, Ian Osterloh
  • Publication number: 20110118224
    Abstract: The present invention is related to a use of a steroid sulfatase inhibitor in the manufacture of a medicament for preventing or inhibiting premature uterine contractions. Specifically, the present invention is related to steroid sulfatase inhibitors useful for the preparation of a pharmaceutical formulation for the modulation, notably the inhibition of pre-term labor.
    Type: Application
    Filed: July 27, 2009
    Publication date: May 19, 2011
    Applicant: PREGLEM SA
    Inventors: Ernest Loumaye, Valerie Cayron-Elizondo, Jean-Pierre Gotteland
  • Publication number: 20100190758
    Abstract: Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.
    Type: Application
    Filed: April 18, 2008
    Publication date: July 29, 2010
    Applicant: PreLem S.A.
    Inventors: Bartholomeus C.J.M. Fauser, Ernest Loumaye
  • Publication number: 20100152102
    Abstract: The invention primarily relates to the use of somatostatin or one of the agonistic analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve and, in particular, to reduce the depletion of the ovarian follicular reserve over time in non-menopausal women or to the use of an antagonistic analog of somatostatin for producing a medicament serving to accelerate the start of growing of quiescent follicles in non-menopausal women. The invention also relates to in vitro applications of somatostatin and of agonistic and antagonistic analogs thereof.
    Type: Application
    Filed: December 3, 2009
    Publication date: June 17, 2010
    Applicant: Preglem S.A.
    Inventors: Alain GOUGEON, Ernest Loumaye
  • Patent number: 7671027
    Abstract: The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of woman. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: March 2, 2010
    Assignee: PregLem S.A.
    Inventor: Ernest Loumaye